Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan · Delayed Price · Currency is TWD 25.85
+0.35 (1.37%)
Aug 26, 2026, 1:26 PM CST
Advagene Biopharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -91.05 | -68.29 | -69.42 | -92.11 | -118.38 | -92.69 |
Depreciation & Amortization | 4.55 | 2.19 | 2.18 | 5.86 | 6.4 | 7.03 |
Other Amortization | - | - | - | 6.14 | 5.2 | 0.7 |
Loss (Gain) From Sale of Investments | - | - | - | - | - | -0.05 |
Stock-Based Compensation | 0.02 | - | - | - | - | - |
Other Operating Activities | 0.06 | -0.16 | -0.16 | -0.08 | 0.12 | 0.16 |
Change in Accounts Receivable | - | - | 0.01 | - | - | 3.99 |
Change in Accounts Payable | 2.97 | 3.74 | -1.91 | 0.5 | 0.07 | -4.31 |
Change in Other Net Operating Assets | -4.47 | -0.8 | -1.35 | 2 | -2.77 | -3.66 |
Operating Cash Flow | -87.92 | -63.33 | -70.65 | -77.7 | -109.35 | -67.18 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -2.71 | -2.31 | -0.48 | - | -0.21 | -0.52 |
Sale (Purchase) of Intangibles | -10 | - | - | - | -10 | - |
Investment in Securities | 90 | 70 | -89.5 | 25 | 124.5 | -79.5 |
Other Investing Activities | - | - | -0.01 | 1.5 | - | -1.5 |
Investing Cash Flow | 77.29 | 67.7 | -89.99 | 26.5 | 114.29 | -81.52 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -1.85 | -1.74 | -1.93 | -1.83 | -1.79 |
Net Debt Issued (Repaid) | -1.88 | -1.85 | -1.74 | -1.93 | -1.83 | -1.79 |
Issuance of Common Stock | 260 | - | 150 | 100.31 | 0.57 | 42.93 |
Financing Cash Flow | 258.12 | -1.85 | 148.26 | 98.38 | -1.26 | 41.14 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 247.5 | 2.52 | -12.38 | 47.18 | 3.67 | -107.56 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -90.62 | -65.64 | -71.12 | -77.7 | -109.56 | -67.7 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.51 | -1.10 | -1.30 | -1.54 | -2.22 | -1.39 |
Levered Free Cash Flow | -67.78 | -41.78 | -46.06 | -43.87 | -76.12 | -55.71 |
Unlevered Free Cash Flow | -67.69 | -41.67 | -45.96 | -43.85 | -76.07 | -55.63 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.18 | 0.18 | 0.15 | 0.04 | 0.08 | 0.13 |
Cash Income Tax Paid | 0.16 | 0.16 | 0.16 | 0.08 | -0.12 | -0.16 |
Change in Working Capital | -1.5 | 2.93 | -3.25 | 2.5 | -2.7 | 17.68 |